The collaboration was originally signed in 2004 to ensure sufficient production capacity from several facilities, and distribution of Imvamune to various international markets as Bavarian Nordic did not have the production capacity to manufacture the drug alone. Now Bavarian Nordic has the capacity to produce the expected order.
According to Bavarian, termination of the agreement will not have any negative financial consequences for the companies.
Production, marketing and distribution of Imvamune will be handled by Bavarian Nordics own production facility and sales organization, combined with local and regional agents and distributors experienced in delivering on government contracts.
“We are now capable of handling production and marketing of Imvamune to the authorities ourselves,” said Peter Wulff, president & CEO of Bavarian Nordic.
Bavarian Nordic said that should the demand exceed its capacity discussions on a future collaboration with GSK may be resumed.